News from sun pharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 21, 2018, 09:04 ET Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries...


Feb 12, 2018, 08:12 ET Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries...


Oct 23, 2017, 09:00 ET Sun Dermatology Launches ABSORICA® (isotretinoin) Tracker App to Help Patients Track Progress

Today, Sun Pharma launched ABSORICA Tracker App to help patients get the most out of their treatment. The smooth, easy-to-use interface is designed...


May 24, 2017, 08:03 ET Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab

Sun Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries or...


Mar 01, 2017, 09:35 ET Sun Pharma Announces Data from Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting

Sun Pharmaceutical Industries Ltd (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries or...


Jan 23, 2017, 08:58 ET Sun Pharma Introduces "Leave Acne Behind™" Patient Initiative in USA

Sun Pharma has introduced "Leave Acne Behind™", an unique initiative dedicated to educate patients and create awareness of severe recalcitrant...


Jan 06, 2017, 12:13 ET Sun Pharma gibt positive Topline-Ergebnisse der konfirmatorischen klinischen Phase-3-Studie für Seciera™ zur Behandlung des Trockenen Auges bekannt

- Seciera™ erreicht ersten und wichtigen zweiten Endpunkt in Schlüsselstudie - Zeigt Wirksamkeit bei 12 Behandlungswochen - Sun Pharma entwickelt...


Jan 05, 2017, 12:37 ET Sun Pharma annonce des résultats initiaux positifs pour l'essai clinique de confirmation de phase 3 de Seciera™ pour le traitement de la sécheresse oculaire

- Seciera™ satisfait les critères d'évaluation primaires et les principaux critères d'évaluation secondaires lors de l'essai pivot - Se révèle...


Jan 04, 2017, 10:44 ET Sun Pharma anuncia resultados positivos de línea superior del ensayo clínico de fase 3 confirmatorio para Seciera™ para tratar el ojo seco

- Seciera™ cumple las conclusiones primarias y secundarias en un ensayo pivotal - Muestra eficacia a las 12 semanas de tratamiento - Sun Pharma está...


Jan 04, 2017, 08:34 ET Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry Eye

- Seciera™ Meets Primary and Key Secondary Endpoints in Pivotal Trial - Shows Efficacy at 12 Weeks of Treatment - Sun Pharma is Developing Seciera™...


Jan 04, 2017, 06:45 ET Sun Pharma anuncia resultados positivos de primeira linha para o teste clínico fase 3 confirmatório da Seciera™, para tratamento do olho seco

A Sun Pharma anunciou os bem-sucedidos resultados do teste clínico fase 3 confirmatório para Seciera™ (solução oftalmológica de ciclosporina A,...


Jan 04, 2017, 05:11 ET Sun Pharma anuncia los principales resultados positivos de ensayo clínico confirmatorio de Fase 3 de Seciera™ para el tratamiento de ojo seco

Sun Pharma anunció resultados exitosos de ensayos clínicos confirmatorios de Fase 3 de Seciera™ (ciclosporina A, 0,09% solución oftálmica), para el...


Oct 01, 2016, 05:05 ET Sun Pharma to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoriasis

Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or...


Jul 27, 2016, 01:59 ET Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis

Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or...


Jul 11, 2016, 11:02 ET Sun Pharma lanza Gemcitabine InfuSMART

- Sun Pharma lanza Gemcitabine InfuSMART, la primera bolsa lista para administrar autorizada del mundo para el tratamiento oncológico - El...


Jul 11, 2016, 09:28 ET Sun Pharma lance Gemcitabine InfuSMART, la première poche de traitement oncologique prête à l'administration autorisée au monde

- Le lancement de la poche InfuSMART se fera d'abord en Europe, où il est prévu de la mettre à disposition dans six pays dans les mois à venir :...


Jul 11, 2016, 09:08 ET Sun Pharma bringt Gemcitabine InfuSMART, den weltweit ersten zugelassenen gebrauchsfertigen Infusionsbeutel für die onkologische Behandlung, auf den Markt

- Markteinführung von InfuSMART beginnt in Europa und ist in den kommenden Monaten in sechs Ländern geplant: Niederlande, Vereinigtes Königreich,...


Jul 11, 2016, 01:27 ET Sun Pharma Launches Gemcitabine InfuSMART, World's First Licensed Ready-to-administer Bag for Oncology Treatment

- InfuSMART Roll-out Begins in Europe; Planned Across Six Countries - Netherlands, UK, Spain, Germany, Italy and France Over Next Few Months -...


Feb 01, 2016, 06:30 ET Sun Pharma launches Imatinib Mesylate in USA

Sun Pharma announced launch of Imatinib Mesylate Tablets (therapeutic equivalent to Gleevec® for indications approved by the FDA) in the US market....


Dec 02, 2015, 08:00 ET Sun Pharma announces its association with World Champion Snowboarder Kelly Clark for Absorica®

Sun Pharma, today, announced its association with gold medalist snowboarder and 2015 ESPY Best Female Action Sports Athlete Kelly Clark. Through this ...


Mar 25, 2015, 07:29 ET Sun Pharma announces closure of merger deal with Ranbaxy

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715), today, begins the integration of Ranbaxy's...